Tuesday, March 18, 2025
Los Angeles, California
The Long-Acting Hepatitis B Workshop brought together clinicians, researchers, regulatory experts, investors, and business leaders to explore the potential for long-acting therapies to transform hepatitis B treatment. Through a series of expert panels and discussions, participants considered the clinical need, regulatory pathways, business models, and investment strategies critical to advancing the field.
The meeting served as a forum to connect scientific innovation with commercial opportunity, drawing lessons from the success of long-acting therapies in HIV, contraception, and other areas. The Workshop featured keynote overviews, summaries of existing preclinical work, two expert panel discussions, and an investor roundtable. Below, you’ll find the full agenda and additional resources from the event.
SESSION 1 – Norah Terrault, Chair.
Public Health and Medical Imperative for Long-Acting HBV Treatments
Funmi Lesi, World Health Organization
Global Public Health Significance
[Presentation] (due to technical issues, the presentation is already in progress)
Chari Cohen, Hepatitis B Foundation
Target Product Profile - Perspective of Persons Living with Hepatitis B
[Presentation]
Jordan Feld, Toronto General Hospital Research Institute
Target Product Profile - Medical Perspective
[Presentation]
Paul Domanico, Clinton Health AccessInitiative
Market Forecast
[Presentation]
SESSION 2– Andrew Owen, Chair.
Existing Preclinical Work
Arnab Chatterjee, Calibr-Skag
ETV Prodrug
[Presentation]
Marc Baum, Calibr-Skag
Oak Crest Institute of Science
[Presentation]
Benson Edagwa, University of Nebraska Medical Center
Long-Acting Tenofir Prodrug Formulations
[Presentation] (due to technical issues, the presentation is already in progress)
Rodney Ho, University of Washington
TFV-Based Treatments
[Presentation]
SESSION 3– Veronica Miller, Chair.
Industry and Investor Perspective Panel
David Thomas, Johns Hopkins University
Paul Domanico, Clinton Health Access Initiative
Regulatory Considerations for Long-Acting Anti-HBV Formulations
[Presentation]
Mila Maistat, Medicines Patent Pool
Low- and Middle-Income Access
[Presentation]
Charles Flexner, Johns Hopkins University
Lessons from HIV Drug Development
[Presentation]
SESSION 4– Mark Sulkowski, Chair.
The Investment Case for Long-Acting HBV Treatments
Robert Gish, Gish Consulting, LLC
Douglas Mayers, DLM Therapeutics, LLC
Anuj Gaggar, Assembly Bio
Leonard Yaffe, Kessef Capital Management, LLC
[Discussion]